Minerva Neurosciences Dividendos y recompras

Dividendo controles de criterios 0/6

Minerva Neurosciences no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

Rendimiento de la recompra

Rendimiento total para el accionista	0%
Rendimiento futuro de los dividendos	n/a
Crecimiento de los dividendos	n/a
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Ratio de pago	n/a

Últimas actualizaciones de dividendos y recompras

No hay actualizaciones

Recent updates

Minerva says FDA declined to accept marketing application for schizophrenia drug

Oct 17

Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Deliver On Growth Plans?

Jan 26

Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation

Oct 02

Minerva Neurosciences' (NASDAQ:NERV) Shareholders Are Down 59% On Their Shares

Mar 03

What You Need To Know About Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Investor Composition

Jan 27

We're Keeping An Eye On Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Rate

Dec 23

A Potential Trade Arises On Minerva

Dec 09

A Look At Minerva Neurosciences' (NASDAQ:NERV) Share Price Returns

Nov 18

Minerva Neurosciences EPS beats by $0.03

Nov 02

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de NERV han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de NERV han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Minerva Neurosciences vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de NERV con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (NERV)	n/a
Suelo de mercado 25% (US)	1.4%
Techo de mercado 25% (US)	4.2%
Media de la industria (Biotechs)	2.3%
Analista de previsiones (NERV) (hasta 3 años)	n/a

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de NERV en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de NERV en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de NERV para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que NERV no ha comunicado ningún pago.

Minerva Neurosciences Dividendos y recompras

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos y recompras

Recent updates

Minerva Neurosciences, Inc., Annual General Meeting, Dec 05, 2024

Minerva Neurosciences Receives Second Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed Securities Requirement under Nasdaq Listing Rule 5550(b)(2)

Minerva Neurosciences Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed Securities Requirement Nasdaq's Listing Rule 5550(b)(2)

Minerva Neurosciences, Inc., Annual General Meeting, Sep 27, 2023

Minerva Neurosciences, Inc. announced that it expects to receive $19.999994 million in funding from Frazier Healthcare Partners, Boehringer Ingelheim International GmbH

Nasdaq Determines to Delist Minerva Neurosciences' Securities from The Nasdaq Capital Market

Minerva Neurosciences, Inc. to Report Q1, 2023 Results on May 15, 2023

Minerva Neurosciences, Inc. Announces Board Changes

Minerva Neurosciences, Inc. Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Minerva Neurosciences Receives Non-Compliance Notice from The Nasdaq Stock Market LLC

Minerva Neurosciences, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Minerva Neurosciences, Inc. Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Minerva says FDA declined to accept marketing application for schizophrenia drug

Minerva Neurosciences: Biotech On The Move

Minerva Neurosciences, Inc. Submits New Drug Application to Fda for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

Minerva stock rises on filing for FDA approval of schizophrenia therapy

We're Hopeful That Minerva Neurosciences (NASDAQ:NERV) Will Use Its Cash Wisely

Insufficient new directors

Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Price target decreased to US$6.67

Minerva Neurosciences, Inc. Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin

Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Deliver On Growth Plans?

Price target increased to US$8.33

Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation

Consensus revenue estimates fall to US$400.0k

Minerva Neurosciences, Inc.(NasdaqGM:NERV) dropped from Russell 3000E Growth Index

Investor sentiment improved over the past week

Consensus forecasts updated

Minerva Neurosciences, Inc. Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension

Investor sentiment deteriorated over the past week

Analysts update estimates

Earnings beat expectations, revenue disappoints

Minerva Neurosciences' (NASDAQ:NERV) Shareholders Are Down 59% On Their Shares

Minerva Neurosciences, Inc. to Report Q4, 2020 Results on Mar 08, 2021

What You Need To Know About Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Investor Composition

Bernstein Liebhard LLP Reminds Investors in SPLK, NAK, and NERV of Filing Deadlines

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Minerva Neurosciences, Inc

We're Keeping An Eye On Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Rate

New 90-day low: US$2.58

Block & Leviton LLP Announces That It Has Filed A Lawsuit Against Minerva Neurosciences, Inc. for Securities Fraud

A Potential Trade Arises On Minerva

A Look At Minerva Neurosciences' (NASDAQ:NERV) Share Price Returns

New 90-day high: US$3.59

Earnings miss expectations

Minerva Neurosciences EPS beats by $0.03

Minerva Neurosciences, Inc. to Report Q3, 2020 Results on Nov 02, 2020

New 90-day low - US$3.21

Minerva Neurosciences, Inc.(NasdaqGM:NERV) dropped from Russell Microcap Value Index

Estabilidad y crecimiento de los pagos

Rentabilidad por dividendo vs. Mercado

Pago de beneficios a los accionistas

Pago en efectivo a los accionistas

Descubre empresas que pagan buenos dividendos